Company: BLLN
Filing Date: 2025-06-20
Form Type: DRS
Source: 0000950123-25-006095
Chunk: 186

Company: BillionToOne, Inc.
Filing Date: 2025-06-20
Form: DRS
Chunk 186
---
star Select tests allow us to broaden the use of Northstar Response without incurring significant losses. If we were to receive increased coverage and reimbursement for Northstar Response, it would lead to
a significant increase in our revenue as the adoption of the test will have already been established.

Outside of our direct sales efforts in oncology, we have
signed collaboration agreements with a select number of pharmaceutical companies and institutions to support clinical development of novel precision oncology therapeutics. These collaborations utilize our existing Northstar products, as opposed to
developing new assays that are specifically tailored to each agreement.

We are driving and leading a paradigm shift within precision diagnostics. Our vision is to leverage our novel single-molecule
next-generation sequencing (smNGS) platform to develop ultrasensitive diagnostic tests that

148

enable personalized solutions and enhance patient outcomes. Our growth strategy to achieve this goal includes the following elements:

| • |     | Drive increased adoption of our existing products in the prenatal and oncology markets.                                                                                                                                                                  
 Healthcare professionals have increasingly incorporated our UNITY tests into their clinical practices to adopt what we believe will be the new standard of care. There are three main opportunities to expand our market penetration of our UNITY        
 prenatal products. First, we believe that we have a significant opportunity for footprint expansion and are continuing to invest in increasing our sales team size to cover new geographies, with aggressive recruiting targets. Second, we believe that 
 our current sales team has only just begun to penetrate their existing territories and, over time, more clinics will adopt our tests in an existing sales territory. Finally, we typically see significant growth once we have gained adoption in a      
 clinic, as additional physicians in those clinics adopt our tests.                                                                                                                                                                                       |

We are in the early stages of executing the same sales strategy in oncology. We will continue to drive adoption of our tests by working closely with physicians, medical societies, payors, and patient advocacy groups to educate them on the benefits of our products. We also believe that our commitment to quality customer experience, through patient education, patient self-service, streamlined testing, and patient-friendly billing, will help maintain and enhance usage of our tests. With our Northstar product line, our commercial efforts have just begun, with our field sales team covering only a fraction of the geography. We have significant room to grow, via more geographical expansion, more penetration within existing sales territories, as well as within existing clinics.

| • |     | Build beyond our extensive library of clinical evidence to support favorable coverage and reimbursement. In